Follicular Lymphoma-Pipeline Review, H1 2015

Follicular Lymphoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6690IDB
  • |
  • Pages: 438
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Follicular Lymphoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Follicular Lymphoma-Pipeline Review, H1 2015', provides an overview of the Follicular Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Follicular Lymphoma Overview 10

Therapeutics Development 11

Pipeline Products for Follicular Lymphoma-Overview 11

Pipeline Products for Follicular Lymphoma-Comparative Analysis 12

Follicular Lymphoma-Therapeutics under Development by Companies 13

Follicular Lymphoma-Therapeutics under Investigation by Universities/Institutes 18

Follicular Lymphoma-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Follicular Lymphoma-Products under Development by Companies 22

Follicular Lymphoma-Products under Investigation by Universities/Institutes 27

Follicular Lymphoma-Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Accentia Biopharmaceuticals, Inc. 29

Affimed Therapeutics AG 30

AmpliMed Corporation 31

Bayer AG 32

Bio-Path Holdings, Inc. 33

Biocon Limited 34

Biogenomics Limited 35

Biothera, Inc. 36

Boehringer Ingelheim GmbH 37

Bristol-Myers Squibb Company 38

Celgene Corporation 39

Celltrion, Inc. 40

Cellular Biomedicine Group, Inc. 41

CTI BioPharma Corp. 42

CureTech Ltd. 43

Curis, Inc. 44

Dynavax Technologies Corporation 45

Eisai Co., Ltd. 46

Emergent BioSolutions Inc. 47

EpiZyme, Inc. 48

F. Hoffmann-La Roche Ltd. 49

Genentech, Inc. 50

Genmab A/S 51

Gilead Sciences, Inc. 52

GlaxoSmithKline Plc 53

ImmunoGen, Inc. 54

Immunomedics, Inc. 55

Infinity Pharmaceuticals, Inc. 56

Johnson & Johnson 57

Karyopharm Therapeutics, Inc. 58

Kite Pharma, Inc. 59

MedImmune, LLC 60

Merck & Co., Inc. 61

Millennium Pharmaceuticals, Inc. 62

Mirati Therapeutics Inc. 63

MorphoSys AG 64

Nordic Nanovector AS 65

Novartis AG 66

Ono Pharmaceutical Co., Ltd. 67

Pfizer Inc. 68

Pharmacyclics, Inc. 69

Portola Pharmaceuticals, Inc. 70

ProNAi Therapeutics, Inc. 71

Sandoz International GmbH 72

Seattle Genetics, Inc. 73

TG Therapeutics, Inc. 74

Follicular Lymphoma-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 81

Assessment by Route of Administration 84

Assessment by Molecule Type 86

Drug Profiles 88

abexinostat hydrochloride-Drug Profile 88

ACP-196-Drug Profile 91

AFM-11-Drug Profile 93

alisertib-Drug Profile 94

ASN-002-Drug Profile 98

atezolizumab-Drug Profile 99

azacitidine-Drug Profile 102

Betalutin-Drug Profile 105

bortezomib-Drug Profile 107

BP-100102-Drug Profile 113

buparlisib hydrochloride-Drug Profile 114

BVX-20-Drug Profile 118

CBM-C19.1-Drug Profile 119

CBM-C20.1-Drug Profile 120

Cell Therapy to Target CD22 for B-Cell Leukemia and Lymphoma-Drug Profile 121

Cell Therapy to Target GM-CSF for Oncology-Drug Profile 123

cerdulatinib-Drug Profile 125

copanlisib hydrochloride-Drug Profile 126

CUDC-907-Drug Profile 130

daratumumab-Drug Profile 132

dasiprotimut-T-Drug Profile 135

denintuzumab mafodotin-Drug Profile 137

duvelisib-Drug Profile 138

E-6438-Drug Profile 141

E-7449-Drug Profile 143

epratuzumab-Drug Profile 144

GS-9901-Drug Profile 149

GS-9973-Drug Profile 150

GSK-2816126-Drug Profile 151

ibrutinib-Drug Profile 152

ibrutinib + ublituximab + TGR-1202-Drug Profile 159

idelalisib-Drug Profile 160

imexon-Drug Profile 163

IMGN-529-Drug Profile 165

IMMU-114-Drug Profile 167

Imprime PGG-Drug Profile 168

interferon alfa-2b-Drug Profile 172

interferon alfa-2b (recombinant)-Drug Profile 173

ixazomib citrate-Drug Profile 174

JNJ-64052781-Drug Profile 178

KTE-C19 CAR-Drug Profile 179

lenalidomide-Drug Profile 181

MEDI-0680-Drug Profile 185

MEDI-551-Drug Profile 186

mocetinostat-Drug Profile 188

MOR-208-Drug Profile 191

moxetumomab pasudotox-Drug Profile 193

nivolumab-Drug Profile 195

obinutuzumab-Drug Profile 201

ofatumumab-Drug Profile 204

Oncoquest-Drug Profile 209

otlertuzumab-Drug Profile 211

pembrolizumab-Drug Profile 213

pidilizumab-Drug Profile 220

pixantrone dimaleate-Drug Profile 222

PNT-2258-Drug Profile 226

polatuzumab vedotin-Drug Profile 228

rituximab biosimilar-Drug Profile 230

rituximab biosimilar-Drug Profile 232

rituximab biosimilar-Drug Profile 233

rituximab biosimilar-Drug Profile 234

rituximab biosimilar-Drug Profile 235

rituximab biosimilar-Drug Profile 236

SD-101-Drug Profile 237

selinexor-Drug Profile 239

SGN-CD70A-Drug Profile 244

SH-7129-Drug Profile 245

temsirolimus-Drug Profile 247

TGR-1202-Drug Profile 249

tisagenlecleucel-T-Drug Profile 251

ublituximab [INN] + TGR-1202-Drug Profile 253

ulocuplumab-Drug Profile 254

urelumab-Drug Profile 256

Vaccine for Follicular Lymphoma-Drug Profile 258

Vaccine for Multiple Myeloma and Follicular Lymphoma-Drug Profile 259

venetoclax-Drug Profile 260

vorinostat-Drug Profile 263

Follicular Lymphoma-Recent Pipeline Updates 267

Follicular Lymphoma-Dormant Projects 416

Follicular Lymphoma-Discontinued Products 418

Follicular Lymphoma-Product Development Milestones 420

Featured News & Press Releases 420

Appendix 431

Methodology 431

Coverage 431

Secondary Research 431

Primary Research 431

Expert Panel Validation 431

Contact Us 431

Disclaimer 432

List of Tables

Number of Products under Development for Follicular Lymphoma, H1 2015 17

Number of Products under Development for Follicular Lymphoma-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Development by Companies, H1 2015 (Contd..4) 32

Products under Investigation by Universities/Institutes, H1 2015 33

Follicular Lymphoma-Pipeline by AbbVie Inc., H1 2015 34

Follicular Lymphoma-Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 35

Follicular Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 36

Follicular Lymphoma-Pipeline by AmpliMed Corporation, H1 2015 37

Follicular Lymphoma-Pipeline by Bayer AG, H1 2015 38

Follicular Lymphoma-Pipeline by Bio-Path Holdings, Inc., H1 2015 39

Follicular Lymphoma-Pipeline by Biocon Limited, H1 2015 40

Follicular Lymphoma-Pipeline by Biogenomics Limited, H1 2015 41

Follicular Lymphoma-Pipeline by Biothera, Inc., H1 2015 42

Follicular Lymphoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 43

Follicular Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 44

Follicular Lymphoma-Pipeline by Celgene Corporation, H1 2015 45

Follicular Lymphoma-Pipeline by Celltrion, Inc., H1 2015 46

Follicular Lymphoma-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 47

Follicular Lymphoma-Pipeline by CTI BioPharma Corp., H1 2015 48

Follicular Lymphoma-Pipeline by CureTech Ltd., H1 2015 49

Follicular Lymphoma-Pipeline by Curis, Inc., H1 2015 50

Follicular Lymphoma-Pipeline by Dynavax Technologies Corporation, H1 2015 51

Follicular Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 52

Follicular Lymphoma-Pipeline by Emergent BioSolutions Inc., H1 2015 53

Follicular Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 54

Follicular Lymphoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55

Follicular Lymphoma-Pipeline by Genentech, Inc., H1 2015 56

Follicular Lymphoma-Pipeline by Genmab A/S, H1 2015 57

Follicular Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 58

Follicular Lymphoma-Pipeline by GlaxoSmithKline Plc, H1 2015 59

Follicular Lymphoma-Pipeline by ImmunoGen, Inc., H1 2015 60

Follicular Lymphoma-Pipeline by Immunomedics, Inc., H1 2015 61

Follicular Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 62

Follicular Lymphoma-Pipeline by Johnson & Johnson, H1 2015 63

Follicular Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 64

Follicular Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 65

Follicular Lymphoma-Pipeline by MedImmune, LLC, H1 2015 66

Follicular Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 67

Follicular Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 68

Follicular Lymphoma-Pipeline by Mirati Therapeutics Inc., H1 2015 69

Follicular Lymphoma-Pipeline by MorphoSys AG, H1 2015 70

Follicular Lymphoma-Pipeline by Nordic Nanovector AS, H1 2015 71

Follicular Lymphoma-Pipeline by Novartis AG, H1 2015 72

Follicular Lymphoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 73

Follicular Lymphoma-Pipeline by Pfizer Inc., H1 2015 74

Follicular Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 75

Follicular Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 76

Follicular Lymphoma-Pipeline by ProNAi Therapeutics, Inc., H1 2015 77

Follicular Lymphoma-Pipeline by Sandoz International GmbH, H1 2015 78

Follicular Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 79

Follicular Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 80

Assessment by Monotherapy Products, H1 2015 81

Assessment by Combination Products, H1 2015 82

Number of Products by Stage and Target, H1 2015 84

Number of Products by Stage and Mechanism of Action, H1 2015 88

Number of Products by Stage and Route of Administration, H1 2015 91

Number of Products by Stage and Molecule Type, H1 2015 93

Follicular Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 273

Follicular Lymphoma-Dormant Projects, H1 2015 422

Follicular Lymphoma-Dormant Projects (Contd..1), H1 2015 423

Follicular Lymphoma-Discontinued Products, H1 2015 424

Follicular Lymphoma-Discontinued Products (Contd..1), H1 2015 425

List of Figures

Number of Products under Development for Follicular Lymphoma, H1 2015 17

Number of Products under Development for Follicular Lymphoma-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Products, H1 2015 27

Assessment by Monotherapy Products, H1 2015 81

Assessment by Combination Products, H1 2015 82

Number of Products by Top 10 Targets, H1 2015 83

Number of Products by Stage and Top 10 Targets, H1 2015 83

Number of Products by Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Top 10 Routes of Administration, H1 2015 90

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 90

Number of Products by Top 10 Molecule Types, H1 2015 92

Number of Products by Stage and Top 10 Molecule Types, H1 2015 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

Accentia Biopharmaceuticals, Inc.

Affimed Therapeutics AG

AmpliMed Corporation

Bayer AG

Bio-Path Holdings, Inc.

Biocon Limited

Biogenomics Limited

Biothera, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Celltrion, Inc.

Cellular Biomedicine Group, Inc.

CTI BioPharma Corp.

CureTech Ltd.

Curis, Inc.

Dynavax Technologies Corporation

Eisai Co., Ltd.

Emergent BioSolutions Inc.

EpiZyme, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genmab A/S

Gilead Sciences, Inc.

GlaxoSmithKline Plc

ImmunoGen, Inc.

Immunomedics, Inc.

Infinity Pharmaceuticals, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

MorphoSys AG

Nordic Nanovector AS

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Pharmacyclics, Inc.

Portola Pharmaceuticals, Inc.

ProNAi Therapeutics, Inc.

Sandoz International GmbH

Seattle Genetics, Inc.

TG Therapeutics, Inc.

Follicular Lymphoma Therapeutic Products under Development, Key Players in Follicular Lymphoma Therapeutics, Follicular Lymphoma Pipeline Overview, Follicular Lymphoma Pipeline, Follicular Lymphoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 135500
Site License
USD 4000 INR 271000
Corporate User License
USD 6000 INR 406500



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]